BIOLIGHT LIFE SCIENCES LTD. BioLight Life Sciences Ltd. Stock
Equities
BOLT
IL0010952237
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 338.4 ILa | 0.00% |
|
-4.43% | -34.89% |
| Sales 2022 | 63K 16.66K 6.3M | Sales 2023 | 118K 31.21K 11.8M | Capitalization | 24.12M 6.38M 2.41B |
|---|---|---|---|---|---|
| Net income 2022 | -7M -1.85M -700M | Net income 2023 | -26M -6.88M -2.6B | EV / Sales 2022 | 207 x |
| Net cash position 2022 | 17.1M 4.52M 1.71B | Net cash position 2023 | 8.55M 2.26M 855M | EV / Sales 2023 | 132 x |
| P/E ratio 2022 |
-3.85
x | P/E ratio 2023 |
-0.93
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 43.16% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -3.84% | ||
| Current month | -21.05% | ||
| 1 month | -28.00% | ||
| 3 months | -28.02% | ||
| 6 months | -38.47% | ||
| Current year | -34.89% |
1 week
334.30
344.50
1 month
334.30451.00
Current year
334.30564.90
1 year
334.30758.90
3 years
334.301 364.00
5 years
334.301 467.00
10 years
334.305 100.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 20-04-30 | |
Yifftach Biel
DFI | Director of Finance/CFO | 48 | 15-04-30 |
Ron Neumann
CTO | Chief Tech/Sci/R&D Officer | 69 | 19-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Israel Makov
CHM | Chairman | 84 | 11-04-20 |
Kobi Faigenbaum
BRD | Director/Board Member | 71 | 17-05-10 |
Alla Felder
BRD | Director/Board Member | 50 | 20-03-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 338.4 | 0.00% | 200 |
| 24-04-24 | 338.4 | +1.01% | 1,155 |
| 24-04-21 | 335 | -4.80% | 9,251 |
| 24-04-18 | 351.9 | -0.62% | 9,967 |
| 24-04-17 | 354.1 | -0.84% | 200 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 03:15 am EDT
More quotes
Biolight Life Sciences Ltd, formerly Bio Light Israeli Life Sciences Investments Ltd, is an Israel-based company engaged, through its subsidiaries, in various fields of research and development of pharmaceuticals and medical products and devices. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The Company provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.
| 1st Jan change | Capi. | |
|---|---|---|
| -34.89% | 4.17M | |
| +8.78% | 220B | |
| +8.24% | 185B | |
| +11.16% | 133B | |
| +26.12% | 107B | |
| +0.04% | 62.91B | |
| +16.21% | 53.34B | |
| -1.63% | 47.71B | |
| -1.11% | 40.29B | |
| +12.16% | 39.57B |
- Stock Market
- Equities
- BOLT Stock
